GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » enGene Holdings Inc (NAS:ENGN) » Definitions » Operating Margin %

enGene Holdings (enGene Holdings) Operating Margin % : 0.00% (As of Jan. 2024)


View and export this data going back to 2023. Start your Free Trial

What is enGene Holdings Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. enGene Holdings's Operating Income for the three months ended in Jan. 2024 was $-10.77 Mil. enGene Holdings's Revenue for the three months ended in Jan. 2024 was $0.00 Mil. Therefore, enGene Holdings's Operating Margin % for the quarter that ended in Jan. 2024 was 0.00%.

The historical rank and industry rank for enGene Holdings's Operating Margin % or its related term are showing as below:


ENGN's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -161.26
* Ranked among companies with meaningful Operating Margin % only.

enGene Holdings's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

enGene Holdings's Operating Income for the three months ended in Jan. 2024 was $-10.77 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jan. 2024 was $-32.20 Mil.


enGene Holdings Operating Margin % Historical Data

The historical data trend for enGene Holdings's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

enGene Holdings Operating Margin % Chart

enGene Holdings Annual Data
Trend Oct20 Oct21 Oct22 Oct23
Operating Margin %
- - - -

enGene Holdings Quarterly Data
Oct20 Oct21 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of enGene Holdings's Operating Margin %

For the Biotechnology subindustry, enGene Holdings's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


enGene Holdings's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, enGene Holdings's Operating Margin % distribution charts can be found below:

* The bar in red indicates where enGene Holdings's Operating Margin % falls into.



enGene Holdings Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

enGene Holdings's Operating Margin % for the fiscal year that ended in Oct. 2023 is calculated as

Operating Margin %=Operating Income (A: Oct. 2023 ) / Revenue (A: Oct. 2023 )
=-26.06 / 0
= %

enGene Holdings's Operating Margin % for the quarter that ended in Jan. 2024 is calculated as

Operating Margin %=Operating Income (Q: Jan. 2024 ) / Revenue (Q: Jan. 2024 )
=-10.773 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


enGene Holdings  (NAS:ENGN) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


enGene Holdings Operating Margin % Related Terms

Thank you for viewing the detailed overview of enGene Holdings's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


enGene Holdings (enGene Holdings) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
7171 Rue Frederick Banting, Saint-Laurent, QC, CAN, H4S 1Z9
Website
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Executives
Richard M Glickman director C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Jason David Hanson director, officer: Chief Executive Officer 8125 NORTH HAYDEN ROAD, SCOTTSDALE AZ 85258-2463
Lumira Capital Investment Management Inc. 10 percent owner 141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5
Richard Paul Bryce officer: Chief Medical Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Fonds De Solidarite Des Travailleurs Du Quebec 10 percent owner 545 CREMAZIE BLVD. EAST, SUITE 200, MONTREAL A8 H2M 2W4
Gerald A Brunk director C/O MDS CAPITAL, 245 FIRST ST., STE 1800, CAMBRIDGE MA 02142
Jasper Bos director BOUNDARY HALL, PO BOX 1093, CRICKET SQUARE, GRAND CAYMAN E9 KY1-1102
Grassin Alexandre Jean-rene Erwan officer: Int. Chief Financial Officer 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Anthony Tzeyew Cheung officer: Chief Technology Officer 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Alexander Julian Nichols officer: Pres. & Chief Operating Ofc. 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
James Crowley Sullivan officer: Chief Scientific Officer 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Forbion Growth Sponsor Feac I B.v. 10 percent owner GOOIMEER 2 35,, NAARDEN P7 1411DC
Forbion Growth Opportunities Fund I Cooperatief U.a. 10 percent owner GOOIMEER 235, 1411 DC, NAARDEN P7 00000
Forbion Growth Management B.v. 10 percent owner C/O FORBION EUROPEAN ACQUISITION CORP., 4001 KENNETT PIKE, SUITE 302, WILMINGTON DE 19807

enGene Holdings (enGene Holdings) Headlines